US Department of Defense Funds Phase 2 Trial of TapImmune Breast Cancer Vaccine

US Department of Defense Funds Phase 2 Trial of TapImmune Breast Cancer Vaccine
The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $3.7 million to conduct a Phase 2 trial of TapImmune’s HER2-targeted T-cell vaccine in women with the breast cancer known as ductal carcinoma in situ (DCIS). The 40 to 45 women who will be enrolled in the study, which is expected to begin this

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *